Identification of Novel Small‐Molecule Inhibitors Targeting KDM5B and Evaluation of Their Antitumour Effects
Cancer Medicine · 2026
DOI: 10.1002/cam4.72058 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2026. Verfasst von Tomoaki Hara und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Data Science, Center of Medical Innovation and Translational Research, Graduate School of Medicine, The University of Osaka, Su…. Hauptthemen laut MEDLINE: Jumonji Domain-Containing Histone Demethylases, Antineoplastic Agents, Repressor Proteins, Nuclear Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Science and Technology Agency.
Abstract (Originalsprache)
KDM5B, a member of the KDM5 family of histone demethylases, plays a critical role in transcriptional repression by demethylating H3K4me2/3. It regulates key biological processes such as development, stem cell maintenance, and oncogenesis, and its aberrant expression is implicated in various cancers. Accordingly, KDM5B is considered a promising therapeutic target in cancer drug discovery. In this study, we performed a screening to identify novel inhibitors of KDM5B. Through this screening, we identified a common core scaffold associated with KDM5B inhibitory activity, and subsequent optimization of the side‐chain structures led to the identification of a series of compounds with IC 50 values ranging from several nanomolar to several micromolar. Evaluation of growth inhibitory activity using the JFCR39 human cancer cell line panel revealed that the final lead compounds, JB‐157 and JB‐161, exhibited GI 50 values in the low micromolar range. In a xenograft model, where the human colorectal cancer cell line HT‐29 was implanted into NOD/SCID mice, administration of these compounds resulted in antitumour effects, with JB‐161 showing particularly pronounced tumor suppression in a subset of treated animals. Furthermore, combination treatment with in vivo CAR‐T cell therapy and JB‐161 in C57BL/6J mice was associated with alterations in chromatin accessibility in tumor and immune cell populations. Taken together, these results suggest that JB‐161 is a candidate KDM5B inhibitor associated with chromatin accessibility changes and antitumour activity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Data Science, Center of Medical Innovation and Translational Research, Graduate School of Medicine, The University of Osaka, Suita, Osaka, Japan.
- Cellular and Molecular Biotechnology Research Institute, National Institute of Advanced Industrial Science and Technology, Tokyo, Japan.
- Department of Gastroenterological Surgery, Graduate School of Medicine, The University of Osaka, Suita, Osaka, Japan.
- Graduate School of Pharmaceutical Sciences, The University of Osaka, Suita, Osaka, Japan.
- Division of Molecular Pharmacology, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan.
- Tokai University Graduate School of Medicine, Isehara, Kanagawa, Japan.
ORCID-Profile: Hidetoshi Eguchi
Förderung
- Japan Science and Technology Agency
Zitieren
APA
Hara, T., Meng, S., Konno, M., Nishida, N., Koseki, J., Meguro, K., Kawano, Y., Morie, T., Dan, S., Satoh, T., Akai, S., Tsujikawa, K., Eguchi, H., Mori, M., Miura, Y., Nishiyama, N., & Ishii, H. (2026). Identification of Novel Small‐Molecule Inhibitors Targeting KDM5B and Evaluation of Their Antitumour Effects. Cancer Medicine. https://doi.org/10.1002/cam4.72058
Vancouver
Hara T, Meng S, Konno M, Nishida N, Koseki J, Meguro K, et al. Identification of Novel Small‐Molecule Inhibitors Targeting KDM5B and Evaluation of Their Antitumour Effects. Cancer Medicine. 2026. doi:10.1002/cam4.72058
BibTeX
@article{Hara2026,
author = {Hara, Tomoaki and Meng, Sikun and Konno, Masamitsu and Nishida, Naohiro and Koseki, Jun and Meguro, Kanji and Kawano, Yasuhiko and Morie, Toshiya and Dan, Shingo and Satoh, Taroh and Akai, Shuji and Tsujikawa, Kazutake and Eguchi, Hidetoshi and Mori, Masaki and Miura, Yutaka and Nishiyama, Nobuhiro and Ishii, Hideshi},
title = {Identification of Novel Small‐Molecule Inhibitors Targeting KDM5B and Evaluation of Their Antitumour Effects},
journal = {Cancer Medicine},
year = {2026},
doi = {10.1002/cam4.72058}
}
EUVIMED